





each L is a ligand that may be the same or different at each occurrence;






X is a linker that may be the same or different at each occurrence;

p is an integer of from 2 to 10;

q is an integer of from 1 to 20;

and wherein L is selected from the group consisting of the following ligands:






Sub  
R2  
cont

and wherein each of said ligands comprises a ligand domain capable of binding to a  $\text{Ca}^{++}$  channel.

53. (New) The compound according to Claim 52, wherein each L is the same at each occurrence.

54. (New) The compound according to Claim 53, wherein q is less than p.

55. (New) The compound according to Claim 54, wherein the linker is represented by the following formula:




in which:

m is an integer from 0 to 20;

X' at each separate occurrence is -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -NR-, -NRR', -C(O)-, -C(O)O-, -C(O)NH-, -C(S)-, -C(S)O-, -C(S)NH- or a covalent bond, where R and R' at each separate occurrence are as defined below for R' and R'';

Z is at each separate occurrence selected from alkylene, substituted alkylene, alkylalkoxy, cycloalkylene, substituted cycloalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, substituted arylene, heteroarylene, heterocyclene, substituted heterocyclene, crown compounds or a covalent bond;

Y' and Y'' at each separate occurrence are selected from -S-S-, a covalent bond or a structure selected from the following group:




in which:

n is 0, 1 or 2; and

R' and R'' at each separate occurrence are selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl or heterocyclic.





*2003* 56. (New) The compound according to Claim 55, wherein p is 2 and q is 1.

57. (New) The compound according to Claim 56, wherein L is selected from the group consisting of the following ligands:




all  
cont

58. (New) The compound according to Claim 56, wherein L is selected from the group consisting of the following ligands:




59. (New) The compound according to Claim 57, wherein L is selected from the group consisting of the following ligands:


Sub  
P 4  
cont.



60. (New) The compound according to Claim 59, wherein the compound is of the following structure:



Sub  
RS  
61. (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of one or more compounds represented by Formula I:



I

where





each L is a ligand that may be the same or different at each occurrence;

X is a linker that may be the same or different at each occurrence;

p is an integer of from 2 to 10;



q is an integer of from 1 to 20;

and wherein L is selected from the group consisting of the following ligands:








Sub  
PS  
Cont.



all  
cont




Sub  
R 5  
cmo-  
and wherein each of said ligands comprises a ligand domain capable of binding to a  $\text{Ca}^{++}$  channel.

62. (New) The composition according to Claim 61, wherein each L is the same at each occurrence.

63. (New) The composition according to Claim 62, wherein q is less than p.

64. (New) The composition according to Claim 63, wherein the linker is represented by the following formula:



in which:










m is an integer from 0 to 20;

X' at each separate occurrence is -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -NR-, -NRR', -C(O)-, -C(O)O-, -C(O)NH-, -C(S)-, -C(S)O-, -C(S)NH- or a covalent bond, where R and R' at each separate occurrence are as defined below for R' and R'';

Z is at each separate occurrence selected from alkylene, substituted alkylene, alkylalkoxy, cycloalkylene, substituted cycloalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, substituted arylene, heteroarylene, heterocyclene, substituted heterocyclene, crown compounds or a covalent bond;

Y' and Y'' at each separate occurrence are selected from -S-S-, a covalent bond or a structure selected from the following group:

all  
cont



in which:







n is 0, 1 or 2; and

R' and R'' at each separate occurrence are selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl or heterocyclic.

8.6  
R6





65. (New) The composition according to Claim 64, wherein p is 2 and q is 1.

66. (New) The composition according to Claim 65, wherein L is selected from the group consisting of the following ligands:



Sub  
P7

67. (New) The composition according to Claim 65, wherein L is selected from the group consisting of the following ligands:



68. (New) The composition according to Claim 65, wherein the compound is of the following structure: